Leaflet Thickening and Immobility in Evolut Low Risk

Leaflet thickening and immobility caused by thrombosis have been reported for both surgical and transcatheter bioprostheses.

Engrosamiento e inmovilidad de las valvas en el Evolut Low Risk

This phenomenon is diagnosed through hypoattenuation, thickening, and lack of motion, as observed through computed tomography (CT) imaging.

The incidence and, especially, the clinical implications of this phenomenon remain unclear, but they are of great interest, particularly in a low-risk population for whom device durability may be affected.

This work is an Evolut Low Risk sub-study that includes patients who were not receiving anticoagulant agents and who were assessed through CT at 30 days and 1 year after transcatheter aortic valve replacement (TAVR) or surgery.

The primary endpoint was the incidence of leaflet thickening at 30 days and 1 year. Imaging scans were analyzed by an independent committee using standardized definitions. Secondary endpoints included reduced leaflet motion, mean aortic gradient, and clinical events.


Read also: Virtual ACC 2020 | First Results of Evolut in Low-Risk Bicuspid Valves.


At 30 days, the rate of thickening was 17.3% for transcatheter valves and 16.5% for surgically-implanted valves. Reduced motion was observed in 14.6% and 14.3% of patients, respectively.

After 1 year, its rate doubled in both patient groups. The rate of thickening in transcatheter valves was 30.9%, compared with 28.4% for surgically-implanted valves, and the rate of reduced motion was 31%, compared with 27%, respectively.

Gradients were not influenced by the presence or severity of thickening and reduced motion at any time during follow-up.


Read also: Meta-Analysis of Large TAVR Studies on Low-Risk: Evidence is Consistent.


The rates for both phenomena observed through CT were similar with supra-annular, self-expanding transcatheter, and surgical bioprostheses.

Conclusion

The presence of CT imaging abnormalities in aortic bioprostheses was frequent, but it did not affect any hemodynamic parameters, at least at 1 year. A longer follow-up is required (particularly in this low-risk population) to determine whether thickening could impact prosthesis durability.

Original Title: Leaflet Thickening or Immobility Following Aortic Valve Replacement: Results from the Evolut Low Risk Sub-study.

Reference: Philipp Blanke et al. Journal of the American College of Cardiology. Journal Pre-proof. https://doi.org/10.1016/j.jacc.2020.03.022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

OPTION Trial: Left Atrial Appendage Closure

Atrial fibrillation ablation is a valid strategy. However, reoccurrence is frequent in these cases, often with asymptomatic presentation. Anticoagulation with warfarin has proven effective in...

TRI-SPA Study: Tricuspid Edge-to-Edge Treatment

Tricuspid regurgitation (TR) is a condition associated with high morbidity and mortality. Currently, surgery is the recommended treatment; however, it carries a high complication...

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...